HANSOH PHARMA lowers CB conversion price to HK$56.54, potential share issuance up 1.5%

Bulletin Express
08/26

Hansoh Pharmaceutical Group Company Limited (HANSOH PHARMA) will adjust the conversion price of its HK$4.68 billion zero-coupon convertible bonds (due 2033) following the interim dividend record date for the six months ended 30 June 2026.

• Conversion price: reduced from HK$57.39 to HK$56.54 per share, effective 28 September 2026.

• Dilution impact: maximum shares issuable on full conversion increases from 81.55 million to 82.77 million, an additional 1.23 million shares (+1.50%).

• Bond size unchanged: outstanding principal remains HK$4.68 billion; all other bond terms are unaffected.

The adjustment complies with the terms of the convertible bonds, reflecting the dividend-related reset mechanism. Chairlady Zhong Huijuan signed the announcement on 26 August 2026.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10